All HIV positive pregnant and breastfeeding women, infants, children, adolescents and adults have been eligible for ART regardless of CD4 count or WHO staging since 01 September 2016. The “Test and Treat All” approach has made it possible for people living with HIV (PLHIV) to access ART timeously. The 2019 Consolidated Guidelines have been revised to include a new formulation of the fixed dose combination (FDC) of tenofovir (TDF) 300 mg + lamivudine (3TC) 300 mg + dolutegravir (DTG) 50 mg (TLD) for all eligible adults, adolescents and children 10 years and older and weighing 35 kg or more. These guidelines have further simplified ART provision and harmonized PMTCT and the management of children, adolescents and adults with HIV/AIDS, TB and other common opportunistic infections.
The guidelines provide guidance for clinicians, managers and trainers on the use of available regimens within the context of the continuum of HIV comprehensive care for prevention, treatment and support for all age groups in private and public sector. These guidelines address clinical and programmatic aspects of HIV treatment and prevention amongst adults, adolescents, children, infants, pregnant and breastfeeding women, and key populations along the continuum of care, including:
- Part 1: The minimum package of HIV prevention, care and treatment services to be offered by a facility
- Part 2: HIV prevention, HIV testing services (HTS) and linkage to care
- Part 3: ART initiation, management of the client on ART, and the prevention and management of coinfections and co-morbidities
- Part 4: PMTCT